Title: HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.
Authors: Luying Xu; Yuxin Xie; Qiheng Gou; Rui Cai; Rong Bao; Yucheng Huang; Ruisi Tang
Abstract: Breast cancer (BC) has the second highest incidence among cancers and is the leading cause of death among women worldwide. The human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20%--30% of BC patients. The development of HER2-targeted drugs, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs) and antibody--drug conjugates (ADCs), has improved the operation rate and pathological remission rate and reduced the risk of postoperative recurrence for HER2- positive early-stage BC (HER2+ EBC) patients. This review systematically summarizes the mechanisms, resistance, therapeutic modalities and safety of HER2-targeted drugs and helps us further understand these drugs and their use in clinical practice for patients with HER2+ EBC.
Subjects: HER2 positive breast cancer; PROTEIN-tyrosine kinase inhibitors; BREAST cancer; NEOADJUVANT chemotherapy; CANCER treatment
Publication: Frontiers in Pharmacology, 2024, p01
ISSN: 1663-9812
Publication type: Academic Journal
DOI: 10.3389/fphar.2024.1446414

HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.

Luying Xu; Yuxin Xie; Qiheng Gou; Rui Cai; Rong Bao; Yucheng Huang; Ruisi Tang